DeepMed Research

BRISTOL MYERS SQUIBB

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With Myelofibrosis

Phase 1

Completed

Conditions: Myelofibrosis

Interventions: Drug: SAR302503 (TG101348)

First Posted Date: 2008-07-29

Last Posted Date: 2025-03-05

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 42

Registration Number: NCT00724334

Locations: 🇺🇸
Investigational Site Number 840105, Boston, Massachusetts, United States
🇺🇸
Investigational Site Number 840102, Stanford, California, United States
🇺🇸
Investigational Site Number 840103, La Jolla, California, United States

and more 3 locations

A Multiple Ascending Dose Study of BMS-650032 in HCV Infected Subjects

Phase 2

Completed

Conditions: Chronic Hepatitis C

Interventions: Drug: BMS-650032
Drug: Placebo

First Posted Date: 2008-07-25

Last Posted Date: 2011-06-27

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 15

Registration Number: NCT00722358

Locations: 🇺🇸
Advanced Clinical Res Inst, Anaheim, California, United States
🇵🇷
Local Institution, Santurce, Puerto Rico
🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States

and more 2 locations

A Belatacept Compassionate Use Study for Patients With a Kidney Transplant

Conditions: Renal Transplantation

First Posted Date: 2008-07-21

Last Posted Date: 2021-11-23

Lead Sponsor: Bristol-Myers Squibb

Registration Number: NCT00719225

Locations: 🇺🇸
Scripps Green Hospital, La Jolla, California, United States
🇺🇸
Tulane Abdominal Transplant Institute, New Orleans, Louisiana, United States
🇺🇸
Office Of Dr. Allan Kirk, Atlanta, Georgia, United States

and more 4 locations

Suboptimal Responders to Adefovir Switching to Entecavir

Phase 4

Completed

Conditions: Hepatitis B, Chronic

Interventions: Drug: Adefovir/Entecavir
Drug: Entecavir

First Posted Date: 2008-07-21

Last Posted Date: 2013-02-11

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 228

Registration Number: NCT00718887

Locations: 🇨🇳
Local Institution, Shanghai, Shanghai, China

Safety Study to Evaluate BMS-767778 in Healthy Subjects and Subjects With Type 2 Diabetes Mellitus (T2DM)

Phase 1

Terminated

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: BMS-767778 or Placebo

First Posted Date: 2008-07-01

Last Posted Date: 2009-02-10

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 120

Registration Number: NCT00707590

Locations: 🇨🇦
Local Institution, Quebec, Canada

Phase I Study in China - Tolerability of a Single Dose of Abatacept 30 mg/kg

Phase 1

Completed

Conditions: Lupus Nephritis

Interventions: Drug: Placebo
Drug: Abatacept

First Posted Date: 2008-06-26

Last Posted Date: 2013-07-30

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 13

Registration Number: NCT00705367

Locations: 🇨🇳
Local Institution, Shanghai, Shanghai, China

A Study of MDX-1106 to Treat Patients With Hepatitis C Infection

Phase 1

Completed

Conditions: Hepatitis C

Interventions: Drug: MDX1106-02
Drug: Placebo

First Posted Date: 2008-06-23

Last Posted Date: 2010-04-23

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 54

Registration Number: NCT00703469

Locations: 🇺🇸
Advanced Clinical Resesarch Institute, Anaheim, California, United States
🇺🇸
Quest Clinical Research, San Francisco, California, United States
🇺🇸
Springfield Clinic Infectious Diseases, Springfield, Illinois, United States

and more 4 locations

Proof of Confidence Study of CCR2 Antagonist (BMS-741672) in Insulin Resistance

Phase 2

Completed

Conditions: Type 2 Diabetes

Interventions: Drug: CCR2 Antagonist
Drug: Placebo

First Posted Date: 2008-06-18

Last Posted Date: 2015-10-12

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 58

Registration Number: NCT00699790

Locations: 🇷🇺
Local Institution, Yaroslavl, Russian Federation

Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic

Phase 2

Completed

Conditions: Metastatic Breast Cancer

Interventions: Drug: Dasatinib
Drug: Letrozole

First Posted Date: 2008-06-12

Last Posted Date: 2016-06-13

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 120

Registration Number: NCT00696072

Locations: 🇺🇸
Florida Cancer Institute - New Hope, Hudson, Florida, United States
🇺🇸
Arizona Oncology Associates D.B.A. Hematology Oncology, Tucson, Arizona, United States
🇺🇸
Central Indiana Cancer Centers, Carmel, Indiana, United States

and more 20 locations

BMS-741672 for Diabetic Neuropathic Pain

Phase 2

Completed

Conditions: Neuropathic Pain

Interventions: Drug: BMS-741672
Drug: Placebo

First Posted Date: 2008-05-23

Last Posted Date: 2015-10-12

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 50

Registration Number: NCT00683423

Locations: 🇺🇸
University Clinical Investigators, Inc., Tustin, California, United States
🇺🇸
Palm Beach Neurological Center, Palm Beach Gardens, Florida, United States
🇺🇸
Research Institute Of Dallas, P.A., Dallas, Texas, United States

and more 5 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy